SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trump's State of the Union address is driving immediate conversation around DJT, generating intensely polarized reactions with supporters praising his "epic" speech while detractors label it a "clown show" "full of lies." Community discussions actively center on his policy claims regarding tariffs, immigration, and the economy, alongside renewed chatter on Epstein-related allegations.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following its CEO's significant presentation at a major cancer summit outlining breakthroughs in 'chemo-free' treatments and recent international regulatory approvals for its ANKTIVA therapy. The community is actively discussing the stock's "unstoppable" scientific progress and the potential for a substantial short squeeze fueled by high short interest.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical ($DRTS) is trending as the community anticipates imminent Japanese marketing approval for its Alpha DaRT cancer treatment, further validated by successful glioblastoma patient outcomes and growing institutional interest, positioning the company for significant global commercial expansion.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending due to upcoming earnings and intense debate surrounding the CLARITY Act's impact on stablecoin yields, with bulls highlighting growing institutional adoption and USDC's foundational role while bears cite regulatory uncertainty, past insider selling, and its price correlation to broader crypto market volatility.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending as its board evaluates Paramount Skydance's revised $31/share all-cash offerwhich includes a ticking fee and covers the $2.8B Netflix breakup feeto determine if it's superior to Netflix's $27.75/share bid, fueling community debate over shareholder value, regulatory risks, and the optimal path for the media giant.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as Warner Bros. Discovery re-evaluates its acquisition offers, granting a limited waiver to re-engage with PSKY following its revised, all-cash bid including substantial regulatory breakup and ticking fees. The community is actively discussing PSKY's offer as potentially superior against Netflix's, while also weighing concerns about the massive debt PSKY would incur if successful.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst an intensified bidding war for Warner Bros. Discovery, as Paramount Skydance's revised offer gives Netflix a limited window to respond. The community is sharply divided on whether Netflix will walk away to collect a $2.8 billion breakup fee and potentially boost its stock, or if it will raise its bid and risk overpaying, further complicated by political pressure and antitrust concerns.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

Cava Group is trending following its earnings report, which showcased robust revenue growth and restaurant expansion, pushing its annual revenue past $1 billion. The community is actively debating the company's valuation and decelerating same-store sales against its ambitious growth plans and strong digital performance.

HP Inc. is an information technology company, which engages in the provision of personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services. It operates through the following segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, solutions and services, and scanning devices. The Corporate Investments segment includes HP Labs and certain business incubation projects. The company was founded by William R. Hewlett and David Packard in 1939 and is headquartered in Palo Alto, CA.

HP Inc

HP Inc. is trending as its latest earnings report paints a divided picture for investors, with weak near-term profit guidance, impacted by U.S. tariffs and supply chain shifts, sparking bearish concerns. Conversely, many in the community are emphasizing the company's compelling value, robust free cash flow, and recently increased dividend, alongside the long-term growth prospects from AI-powered PCs.

Make Iran Great Again

MIGA CRYPTO is trending as a newly launched token on the BNB chain, generating buzz with an immediate promotional airdrop for buyers as the community rallies to "make this token great together."

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

JPMorgan Chase & Co. Increases Position in Corcept Therapeutics Incorporated $CORT

JPMorgan Chase & Co. raised its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 223.4% in the third quarter, according to the company in its most recent filing with the...

<ul class="summary-bullets"><li>The company's Q4 revenue rose to $202.1 million, but net income fell to $24.3 million.</li><li>Corcept said demand for its Cushing syndrome business surged in 2025, with record prescriptions and prescribers.</li><li>Corcept pushed back on the FDA’s decision to reject Relacorilant in December, saying that an April FDA meeting will be critical to determining next steps.</li></ul>Shares of Corcept Therapeutics, Inc. (CORT) slipped in extended trading on Tuesday after weaker-than-expected fourth-quarter (Q4) profit, as investors weighed the setback to its Cushing syndrome drug ahead of a key FDA meeting in April.<a href="https://stocktwits.com/symbol/CORT">CORT stock</a> jumped over 3% in Tuesday’s regular session.<h2 class="st-heading-2">CORT Q4 Results And 2026 Outlook</h2>Corcept reported Q4 revenue of $202.1 million, up from $181.9 million a year earlier but below expectations, while net income fell to $24.3 million, or $0.2 per diluted share, from $30.7 million, or $0.26 per share, also missing estimates.For the full year, revenue rose to $761.4 million from $675.0 million in 2024, while net income declined to $99.7 million from $141.2 million. Corcept guided for full-year 2026 revenue of $900 million to $1 billion.&nbsp;“In 2025, our Cushing’s syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism’s true prevalence and the necessity of appropriate treatment,” CEO Joseph K. Belanoff said, adding that there was a record number of new prescriptions and prescribers.However, Belanoff noted that growth was partially constrained by capacity issues and operational disruptions tied to a specialty pharmacy transition in Q4. He said the transition is now complete, and February is on track to be a record month for new patient starts.<h2 class="st-heading-2">FDA Rejection Keeps Focus On Relacorilant</h2>Investor attention remains centered on Relacorilant after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter in December, refusing approval of the drug for patients with hypercortisolism, also known as Cushing syndrome.In an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cort-shares-plummer-on-fda-drug-rejection-letter-reveal/cmySqTUR4SV">amended letter</a> published last month, the FDA said the late-stage trial results were insufficient to demonstrate effectiveness and flagged concerns around drug-induced liver injury. The agency also said it had raised concerns during pre-submission meetings about the adequacy of Corcept’s clinical development program, particularly regarding the assessment of effects on hypertension, and requested new clinical data and risk mitigation strategies.While the FDA acknowledged that Corcept’s pivotal Grace trial met its primary endpoint and that confirmatory evidence was provided, it said it could not reach a “favorable benefit-risk assessment” without additional evidence in December.<h2 class="st-heading-2">Corcept Pushes Back On FDA Decision</h2>On Tuesday’s earnings call, Corcept pushed back on the FDA’s conclusions and said an April FDA meeting will be critical to understanding the decision.Gary Robb, the company’s chief business officer, said Corcept believes the data “clearly met the hurdle for approval” and were consistent with those supporting previously approved treatments. “The confirmatory evidence we provided also met its endpoint until the agency mentioned sort of an analysis at the end that they performed that we had never seen and really can't replicate,” he added.&nbsp;“There is daylight between our position and their position,” Robb said, adding that the April meeting is intended to clarify the FDA’s thinking and determine next steps.Belanoff cited results from the company’s Catalyst study showing that treating hypercortisolism in certain patients led to symptom improvement. He said it is too early to say whether Corcept will pursue a new randomized trial.<h2 class="st-heading-2">Pipeline Beyond Cushing Syndrome</h2>Separately, Corcept said its New Drug Application for Relacorilant in platinum-resistant ovarian cancer remains under FDA review, with a July 11 deadline for the FDA to decide whether to approve the drug, and a European decision expected later this year.&nbsp;The company also outlined multiple ongoing and planned studies across oncology, metabolic disease and (a<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=Amyotrophic+Lateral+Sclerosis&amp;sca_esv=82030d20fc0d5849&amp;sxsrf=ANbL-n6CsXNcCbD0Jf2HDjdwkbZaPdUv9g%3A1772002173901&amp;ei=fZueaaXPNuOo4-EPjc7WmAQ&amp;biw=1920&amp;bih=911&amp;ved=2ahUKEwj-udm2h_SSAxX1xjgGHc8qLfQQgK4QegYIAAgAEAQ&amp;uact=5&amp;oq=als+full+form%5C&amp;gs_lp=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_E8IHBzAuNC44LjHIBzWACAA&amp;sclient=gws-wiz-serp">myotrophic lateral sclerosis</a>) ALS, including a planned Phase 3 trial of Dazucorilant in ALS by mid-year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CORT was ‘bullish’ amid a 1,200% surge in 24-hour&nbsp; message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cort_ss_png_60f385c217.webp" alt="cort ss.png" width="966" height="140"><figcaption>CORT sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “CORT is a solid, growing company with multiple self-funded catalysts span across endocrinology and oncology. The current SP is an once-in-life-time bargain. GLTA! “<stembedurl>https://stocktwits.com/gucag006/message/645809500</stembedurl>Another user said, “Beaten down and an absolute steal at these prices. This company is going nowhere, buy and hold.”<stembedurl>https://stocktwits.com/The_Scientist/message/645785513</stembedurl>CORT stock has risen 5% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corcept Therapeutics logo is seen displayed on the screen of a tablet

CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst 

The company guided for $900 million to $1 billion in 2026 revenue.

Equity

Corcept Therapeutics Q4 Earnings Call Highlights

Corcept Therapeutics (NASDAQ:CORT) reported higher revenue in 2025 and issued 2026 guidance as executives used the company's fourth-quarter earnings call to address two major setbacks: an adverse...

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT) for...

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept (CORT) delivered earnings and revenue surprises of -24.53% and -20.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc.

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc. CORT Stockholder Notice: Shareholder Rights Law Firm...

Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results, Misses Estimates By $0.07 EPS

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) posted its earnings results on Tuesday. The biotechnology company reported $0.20 EPS for the quarter, missing analysts' consensus estimates of...

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30...

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline Corcept Therapeutics (CORT) Litigation: Hagens...

$CORT Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.23 down -20.69% YoY
• Reported revenue of $202.12M up 11.12% YoY
• Corcept Therapeutics Inc expects higher R&amp;D and SG&amp;A expenses in 2026 as clinical programs advance. The Inflation Reduction Act is also anticipated to limit Medicare revenue and reduce Corcept&#39;s profits in 2026 and beyond.

Stocktwits

Corcept Therapeutics Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.23 down -20.69% YoY
• Reported revenue of $202.12M up 11.12% YoY
• Corcept Therapeutics Inc expects higher R&D and SG&A expenses in 2026 as clinical programs advance. The Inflation Reduction Act is also anticipated to limit Medicare revenue and reduce Corcept's profits in 2026 and beyond.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CORT News

CORTCorcept Therapeutics Inc